share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/19 19:13

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 26,082 shares of the company's Class A Common Stock on August 15, 2024. The transaction was carried out at a price of $6.69 per share, resulting in a total value of approximately $174,488. Following the sale, Gibson directly holds 732,656 shares in the company. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
2024年8月15日,Recursion Pharmaceuticals的CEO Christopher Gibson以每股6.69美元的價格完成了26,082股A類普通股的銷售,總價值約爲174,488美元。銷售後,Gibson直接持有公司的732,656股股票。該銷售是通過交易代碼「F」執行,以涵蓋交付或扣留證券的行權價格或稅收負債的支付。
2024年8月15日,Recursion Pharmaceuticals的CEO Christopher Gibson以每股6.69美元的價格完成了26,082股A類普通股的銷售,總價值約爲174,488美元。銷售後,Gibson直接持有公司的732,656股股票。該銷售是通過交易代碼「F」執行,以涵蓋交付或扣留證券的行權價格或稅收負債的支付。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息